Screening for novel lead compounds targeting benzodiazepine allosteric binding site of wild-type and H129Y variant of GABA_A receptor: an in-silico molecular docking study
by Sai Manohar Thota; Naresh Krishna Narasimha
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 14, No. 5, 2021

Abstract: Classical benzodiazepines (BZDs) bind at the high-affinity BZD binding site of the GABA_A receptor and enhance the natural effect of GABA resulting in anxiolytic, anticonvulsant, muscle relaxation and sedative effects. However, BZDs have unwanted side effects due to drug interaction, abuse and dependence. In addition, GABA_A receptor variants exhibit poor affinity for BZDs and could lead to pharmaco-resistance. Using virtual screening and in silico molecular docking, we have identified novel compounds with a high affinity towards the BZD binding site of the GABA_A receptor. In addition, we have also identified compounds showing high affinity towards the H129Y GABA_A variant, which could act as novel personalised medicines. We have predicted physiochemical, pharmacokinetics and drug-likeness properties of the high-affinity compounds. Further in vitro and in vivo validation could identify novel lead compounds against the BZD allosteric binding site of wild-type and H129Y GABA_A receptor variants.

Online publication date: Fri, 07-Jan-2022

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com